{
    "title": "Mebendazole (Vermox) vs Cancer",
    "inventor_name": null,
    "publication_year": null,
    "device_name": null,
    "goal": "To treat cancer by repurposing the antiparasitic drug mebendazole as a selective anti-tumor agent.",
    "problem_addressed": "Limited efficacy and high toxicity of existing chemotherapy; need for affordable, low-toxicity cancer therapies.",
    "concept_summary": "Mebendazole, an inexpensive antiparasitic drug, interferes with micro-tubule assembly in dividing cells, causing mitotic arrest and apoptosis. Pre-clinical studies and isolated clinical reports suggest it selectively targets cancer cells while sparing normal tissue, offering a potential low-cost cancer treatment.",
    "detailed_description": "Mebendazole (MBZ) is a benzimidazole derivative traditionally used to treat intestinal worms. It inhibits the polymerization of tubulin, disrupting the spindle apparatus required for cell division. This leads to G2-M arrest, activation of apoptotic pathways (including Bcl-2 inactivation), reduced angiogenesis, and inhibition of tumor growth in vitro and in mouse xenograft models. Small case reports indicate disease stabilization in metastatic adrenocortical carcinoma. The drug is orally administered, inexpensive, and has a long safety record, but large-scale clinical trials are lacking and US manufacturing has ceased.",
    "category": "Medical & Dental Technologies",
    "principles": [
        "Micro-tubule depolymerization",
        "Mitotic spindle inhibition",
        "Induction of apoptosis",
        "Anti-angiogenic effects"
    ],
    "scientific_domains": [
        "Oncology",
        "Cell Biology",
        "Pharmacology",
        "Medicine"
    ],
    "mechanisms_of_action": [
        "Inhibits tubulin polymerization -> spindle assembly failure",
        "Triggers G2-M cell-cycle arrest",
        "Activates mitochondrial apoptosis pathways",
        "Reduces tumor angiogenesis"
    ],
    "materials": [
        "Mebendazole (benzimidazole compound)"
    ],
    "energy_sources": [],
    "inputs": [
        "Oral mebendazole tablets (e.g., 100 mg dose)",
        "Optional co-administration of cimetidine (Tagamet) to increase plasma levels"
    ],
    "outputs": [
        "Cancer cell death",
        "Tumor growth inhibition",
        "Extended survival in animal models",
        "Disease stabilization in reported patient case"
    ],
    "claimed_performance": "Effective against multiple cancer types (lung, melanoma, adrenocortical carcinoma, glioblastoma) with minimal toxicity; tumor regression and long-term disease control reported in isolated cases.",
    "experimental_evidence": "Multiple peer-reviewed studies demonstrate dose-dependent inhibition of tumor cell proliferation in vitro, reduction of tumor xenograft growth in mice, and a case report of 19-month disease stabilization in a patient with metastatic adrenocortical carcinoma.",
    "replication_status": "Results reported in the scientific literature; no large-scale independent replication documented in the article.",
    "keywords": [
        "Mebendazole",
        "Cancer",
        "Micro-tubule inhibitor",
        "Drug repurposing",
        "Apoptosis",
        "Chemotherapy",
        "Low-cost therapy"
    ],
    "related_technologies": [
        "Taxol (paclitaxel)",
        "Other micro-tubule inhibitors",
        "Standard chemotherapy agents"
    ],
    "controversy_level": "medium",
    "confidence_score": 0.8,
    "practicability_score": 0.7,
    "fringe_score": 0.3,
    "evidence_strength": 0.6,
    "risk_score": 0.2,
    "trl_estimate": 6,
    "source_urls": [
        "http://www.viewzone.com/mebendazole.html"
    ],
    "organizations": [
        "Janssen Pharmaceutical",
        "Johnson & Johnson",
        "Teva Pharmaceuticals",
        "Gedeon Richter",
        "U.S. Food and Drug Administration"
    ],
    "applications": [
        "Cancer treatment",
        "Adjunct therapy for chemotherapy-resistant tumors"
    ],
    "limitations": [
        "Lack of large, randomized clinical trials",
        "Discontinuation of US manufacturing",
        "Unclear optimal dosing regimen for oncology",
        "Potential regulatory hurdles for off-label use"
    ],
    "open_questions": [
        "What is the efficacy of mebendazole across a broader range of human cancers?",
        "How does mebendazole achieve selectivity for cancer cells over normal cells?",
        "What are the optimal dosing schedules and combination strategies?",
        "Can manufacturing be re-established or alternative suppliers secured?",
        "What are the long-term safety implications of high-dose, prolonged use?"
    ],
    "red_flags": [
        "Reliance on anecdotal case reports and pre-clinical data",
        "Off-label use without regulatory approval",
        "Potential bias in presentation of data",
        "Discontinued production may limit accessibility"
    ],
    "evidence_quotes": [
        "\"Oral administration of MZ in mice elicited a strong antitumor effect in a s.c. model and reduced lung colonies in experimentally induced lung metastasis without any toxicity when compared with paclitaxel-treated mice.\"",
        "\"MZ arrested cells at the G2-M phase before the onset of apoptosis, and resulted in mitochondrial cytochrome c release, followed by apoptotic cell death.\"",
        "\"Mebendazole significantly extended mean survival up to 63% in syngeneic and xenograft orthotopic mouse glioma models.\"",
        "\"His metastases initially regressed and subsequently remained stable while receiving mebendazole as a sole treatment for 19 months.\"",
        "\"Mebendazole is highly selective and somehow targets only cancerous cells (as well as a host of intestinal parasites).\""
    ]
}